Correlations and ADAMTS13 levels at baseline and at recovery. Patients were grouped according to treatments received. Three patients who died early (1 in the capla group, 2 in the noncapla group) had no information regarding postbaseline ADAMTS13 levels and were not considered for calculations. According to treatment scheme, correlations were calculated (A-B) between days on PEX therapy and time elapsed from PEX start to ADAMTS13 recovery ≥20% and (C) between days from PEX start to capla start and days on PEX therapy. ADAMTS13 levels were compared between treatment schemes (D-E) at baseline and (F-G) at recovery ≥20%. For the last comparison, those patients who did not achieve levels ≥20% by the end of the study were not considered. Capla, caplacizumab.